PGG-glucan

Drug Profile

PGG-glucan

Alternative Names: Betafectin

Latest Information Update: 04 Feb 1999

Price : $50

At a glance

  • Originator Alpha-Beta Technology [CEASED]
  • Class Antibacterials; Antineoplastics; Beta Glucans
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Postoperative infections

Most Recent Events

  • 04 Feb 1999 Discontinued-III for Postoperative infections in USA (IV-infusion)
  • 26 May 1998 An in vivo study has been added to the Bacterial Infections phamacodynamics section
  • 28 Apr 1998 A clinical study has been added to the Bacterial Infections therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top